| Ongoing Clinical Trials for the Management of the COVID-19 Pandemic MP Lythgoe, P Middleton Trends in Pharmacological Sciences, 2020 | 427 | 2020 |
| Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease H Abu-Sbeih, DM Faleck, B Ricciuti, RB Mendelsohn, AR Naqash, ... Journal of Clinical Oncology, JCO. 19.01674, 2019 | 151 | 2019 |
| Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with checkpoint inhibitors AR Khaki, A Li, LN Diamantopoulos, MA Bilen, V Santos, J Esther, ... Cancer, 2019 | 76 | 2019 |
| The worldwide clinical trial research response to the COVID-19 pandemic-the first 100 days P Janiaud, C Axfors, J van't Hooft, R Saccilotto, A Agarwal, ... F1000Research 9 (1193), 1193, 2020 | 53 | 2020 |
| Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future MP Lythgoe, CJ Rhodes, P Ghataorhe, M Attard, J Wharton, MR Wilkins Pharmacology & therapeutics 164, 195-203, 2016 | 53 | 2016 |
| Application of “systems vaccinology” to evaluate inflammation and reactogenicity of adjuvanted preventative vaccines DJM Lewis, MP Lythgoe Journal of immunology research 2015, 2015 | 53 | 2015 |
| A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors AR Khaki, A Li, LN Diamantopoulos, NJ Miller, L Carril-Ajuria, ... European Urology Oncology, 2021 | 45 | 2021 |
| Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis SS Malik, MP Lythgoe, M McPhail, KJ Monahan Familial cancer 17 (4), 557-564, 2018 | 45 | 2018 |
| Oncologist-led BRCA ‘mainstreaming’in the ovarian cancer clinic: A study of 255 patients and its impact on their management M Rumford, M Lythgoe, I McNeish, H Gabra, L Tookman, N Rahman, ... Scientific Reports 10 (1), 1-9, 2020 | 44 | 2020 |
| Gene of the month: lymphocyte-activation gene 3 (LAG-3) MP Lythgoe, DSK Liu, NE Annels, J Krell, AE Frampton Journal of Clinical Pathology, 2021 | 40 | 2021 |
| Histologic Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study NJ Miller, AR Khaki, LN Diamantopoulos, MA Bilen, V Santos, N Agarwal, ... The Journal of Urology, 10.1097/JU. 0000000000000761, 2020 | 36 | 2020 |
| Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019 MP Lythgoe, A Desai, B Gyawali, P Savage, J Krell, JL Warner, AR Khaki JAMA Network Open 5 (6), e2216183-e2216183, 2022 | 32 | 2022 |
| Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021 DJ Benjamin, A Xu, MP Lythgoe, V Prasad JAMA Network Open 5 (3), e222265-e222265, 2022 | 32 | 2022 |
| Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada MP Lythgoe, P Middleton JAMA Network Open 4 (6), e2114531-e2114531, 2021 | 32 | 2021 |
| Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies P Middleton, C Hsu, MP Lythgoe BMJ Open Gastroenterology 8 (1), e000739, 2021 | 30 | 2021 |
| Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology MP Lythgoe, V Prasad British Journal of Cancer, 1-3, 2022 | 27 | 2022 |
| Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020 A Haslam, MP Lythgoe, EG Akman, V Prasad JAMA Network Open 4 (11), e2135123-e2135123, 2021 | 25 | 2021 |
| Regulatory decisions diverge over aducanumab for Alzheimer’s disease MP Lythgoe, K Jenei, V Prasad bmj 376, 2022 | 22 | 2022 |
| Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes SM Esagian, AR Khaki, LN Diamantopoulos, L Carril‐Ajuria, D Castellano, ... BJU international, 2021 | 21 | 2021 |
| The Evidence Base of US Food and Drug Administration Approvals of Novel Cancer Therapies from 2000 to 2020. V Gloy, AM Schmitt, P Düblin, J Hirt, C Axfors, H Kuk, TV Pereira, ... International Journal of Cancer, 2023 | 19 | 2023 |
